Aceclofenac Sustained Release Tablets Instructions
Release time:
2020-07-31
核准日期:2009年01月04日
第1次修改日期:2009年03月10日
第2次修改日期:2015年05月05日
悦意宁
醋氯芬酸缓释片说明书
请仔细阅读说明书并在医师指导下使用
[药品名称]
通用名称:醋氯芬酸缓释片
英文名称: Aceclofenac Sustained-release Tablets
汉语拼音:Culvfensuan Huanshi Pian
[成 份]:本品主要成分为:醋氯芬酸
化学名称:2-[(2,6-二氯苯基)胺基]-苯乙酰氧基乙酸
化学结构式:

分子式:C16H13Cl2NO4
分子量:354.19
[性 状] 本品为白色或类白色片
[适 应 症]
骨关节炎、类风湿关节炎和强直性脊椎炎等引起的疼痛和炎症的症状治疗。
[规 格] 0.2g
[用法用量]
口服:必须整片吞服,勿嚼碎。每次0.2g(一片),每日一次,或遵医嘱。
[不良反应]
根据临床试验结果及相关文献报道,本品的不良反应有:
1、常见不良反应
胃肠道系统失调:消化不良、腹痛、恶心和腹泻。
肝胆:肝酶升高
2、偶见不良反应(发生率1%-0.1%)
一般为头晕。胃肠道系统:胀气、胃炎、便秘、呕吐、溃疡性口腔粘膜炎。皮肤:瘙痒、皮疹、皮炎、湿疹。代谢和营养:尿素氮和肌酐升高。
3、罕见不良反应(发生率小于0.1%)
一般有头痛、疲倦、面部浮肿、过敏症状、体重增加。血液:贫血、粒细胞减少、血小板减少、中性粒细胞减少。心血管:、水肿、心悸、腓肠肌痉挛、潮红、紫癜。 泌尿系统:间质性肾炎。中枢和外周神经系统:感觉障碍、震颤。胃肠道系统障碍方:胃肠出血和溃疡、出血性腹泻、肝炎或胰腺炎、柏油状大便、口腔粘膜炎症。皮肤:湿疹。代谢和营养:碱性磷酸酶升高,高钾血症。
精神病学方面:抑郁、多梦、嗜睡、失眠。眼睛:视觉异常。
其他:味觉倒错、脉管炎、。
如其它的非甾体抗炎药,可能发生严重的皮肤粘膜的超敏反应。
[禁忌]
以下患者禁用:
1.已知对本品过敏者;
2.病人服用与本品作用机制相似的非甾体抗炎药如阿斯匹林、双氯芬酸等引起哮喘、支气管痉挛、急性鼻炎者;
3.患有或者怀疑患有胃、十二指肠溃疡者、或有胃、十二指肠溃疡复发史的患者,胃肠道出血或者其他出血或凝血功能障碍者;
4.患有严重心衰、肝肾功能不全者;
5.妊娠最后3个月期间的孕妇禁用。
[注意事项]
1.口服时必须整片吞服,勿嚼碎。嚼碎会影响缓释效果,增加副作用发生的可能性。
2.有胃肠道疾病的患者或有消化道溃疡、脑血管出血、溃疡性结肠炎、Crobn’s病、系统性红斑狼疮(SLE)、卟啉病及造血和凝血功能障碍病史患者应慎用或在密切监控下使用;
3.轻度、中度肝、肾、心功能不全者以及有体液潴留、用利尿药治疗或其他同样有低血容量危险的患者应慎用;
4.服用非甾体消炎药后出现头晕和中枢神经系统其它障碍的患者应避免开车或从事机械操作;
5.长期服用非甾体抗炎镇痛药患者应经常检查,以防对肝肾功能和血细胞计数的不良影响。
[孕妇及哺乳期妇女用药]
抗炎药可能会阻滞子宫收缩和延迟分娩。它们可能引起宫内动脉导管收缩和闭锁,导致新生儿肺动脉高压和呼吸功能不全。抗炎药也可能降低胎儿血小板功能和抑制胎儿肾功能,从而引起羊水过少和新生儿无尿症。故孕妇在妊娠最后三个月禁用本品。本品是否会分泌到母乳中尚不清楚,故哺乳期间妇女不应使用本品,除非医生认为必要。
[儿童用药]
儿童用药的安全性和有效性尚末确定,故不推荐儿童使用。
[老年患者用药]
一般无须降低剂量。但因老年患者更容易出现副作用,也更可能造成肾、心血管和肝功能损害。在治疗期间,很多时候患者无前期症状或明显的病史,结果出现严重的胃肠出血和/或穿孔,使用时应倍加慎重。
[药物相互作用]
1.使用本品时应避免与以下药物合用:
非甾体抗炎药会抑制甲氨喋呤在肾小管的分泌,可能具有轻微的代谢相互作用,从而导致甲氨喋呤清除率降低,故在高剂量甲氨喋呤治疗期间,应始终避免服用非甾体抗炎药物。
某些非甾体抗炎药可抑制锂盐在肾脏的消除过程,使血中锂浓度升高,应避免与锂盐合用,若必须合用,应保证血清中锂水平可以经常测定。
非甾体抗炎药可抑制血小板聚集和损害胃肠粘膜,可增加抗凝药物的活性,从而导致抗凝药用患者胃肠道出血的倾向。应避免本品与香豆素口服抗凝药、噻氯匹定、血栓溶解剂及肝素等合用。
2.本品与以下药物联合用药时需调整剂量或倍加注意:
在使用本品时,即使使用低剂量甲氨喋呤,也应注意它们间可能产生药物相互作用,特别是肾功能不全的患者,如果在24小时内同时使用这两种药,更应警惕,因为甲氨喋呤血药浓度可能会增加而导致毒性增加。
非甾体抗炎药与环孢菌素或他可利一起使用,因前者会降低肾脏前列腺素的合成,肾毒性风险增加,故联合用药时应密切监测肾功能。
同时服用本品和阿斯匹林或其他非甾体抗炎药物会增加副作用机率,应予警惕。
非甾体抗炎药会削弱某些利尿药如呋喃苯胺酸、丁苯胺酸等的利尿作用,也会降低噻嗪利尿药的降压作用,与保钾利尿药同时使用会升高钾水平,故应监测钾;非甾体抗炎药和ACE(血管紧张素转化酶)抑制剂同时使用,会增加失水病人急性肾功能衰竭的危险。
本品与苄氟噻嗪(利尿降压药)联合用药末发现血压控制的影响。但也不能就此排除本品与其他抗高血压药如β-受体拮抗剂的联合使用时的相互作用。
有报道指出,本品可能会引起低血糖,使用时应考虑调整降糖药物的剂量。
3. 本品主要通过细胞色素P4502C9代谢,因此可能与苯妥英钠、地高辛、西米替丁、甲苯磺丁脲、保泰松、胺碘酮、咪康唑和磺胺苯吡唑等发生药物相互作用的风险。
由于本品与血浆蛋白几乎完全结合,那些与蛋白高结合率的药物可能被本品置换,故应注意,需进行监测。
[药物过量]
没有关于人超剂量使用本品的研究数据。过量使用后,可能出现的症状有恶心、呕吐、胃痛、头晕、嗜睡和头痛。此时如果需要,可洗胃,给予活性炭,必要时可使用抗酸药或其他对症治疗。
[药理毒理]
1.药理作用
本品为非甾体抗炎药,具有抗炎、镇痛作用。其作用机理主要是通过抑制环加氧酶活性,从而使前列腺素合成减少。
2.毒理研究
重复给药毒性:大鼠连续经口给药1个月,剂量分别为15、50和100mg/kg/日,结果仅100mg/kg/日组出现动物死亡,并伴有大便潜血,组织病理学检查可见该组动物出现胃或肠道粘膜刺激反应。与其它非甾体抗炎药类似,试验动物对本品的耐受性较差。另外,动物与人的药代动力学差异导致其潜在毒性难以判断,但在大鼠(能将醋氯芬酸代谢为双氯芬酸)和猴(有一部分末代谢的原型药)在最大耐受剂量下给药的毒理试验结果显示,本品末见有非甾体类抗炎药常见毒性以外的其它毒性作用。
遗传毒性:本品遗传毒性试验结果阴性。
生殖毒性:据报道,抗炎药抑制前列腺素合成的作用可能导致严重的胚胎毒性。能抑制子宫收缩,从而导致分娩延迟。可引起子宫内胎儿动脉导管狭窄或关闭,导致新生儿肺动脉高血压和呼吸功能不全。抗炎药还能抑制胎儿血小板功能并影响其肾功能,导致羊水过少和新生儿无尿症。因此,在妊娠最后三个月禁止使用抗炎药。但有文献报道,在妊娠的中、早期本品同样会影响胎儿发肓。目前尚不清楚本品是否经人的乳汁排泄,因此,除非医生认为必要时,哺乳期妇女不应使用本品。
致癌性:在小鼠和大鼠进行的致癌性研究中末见本品有致癌作用。
[药代动力学]
(一)Beagle犬的药代动力学
单剂量灌胃200mg后,本缓释片的Tmax,T1/2,MRT,Cmax分别为:5.0±2.7h,6.03±1.95h,9.79±1.71h,61.36±20.75g/ml。而醋氯芬酸普通片的相应值为:2.3±0.6h,4.97±1.95h,7.41±1.90h,81.35±15.63g/ml。说明本品具有缓释效果。且两制剂的AUC24和AUC生物等效,相对生物利用度为91.42±11.17%。
多剂量灌胃(200mg/天,5天)后,本缓释片与醋氯芬酸普通片稳态的峰浓度、坪浓度、谷浓度、波动系数均无显著差异,稳态情况下的相对生物利用度为93.4%。
(二)人体药代动力学
单剂量口服醋氯芬酸缓释片,经时血药浓度变化过程,符合一级吸收的一房室模型。主要药动学参数为:T1/2Ka(h)=1.30±0.39,T1/2Ke(h)=4.66±0.29,Tmax(h)=4.00±0.46,Cmax(μg·mL-1)=10.87±1.04,MRT(h)=7.52±0.40,AUC0~24(μg·h-1·mL-1)=73.23±10.35, AUC0~∞(μg·h-1·mL-1)=81.81±11.00。多剂量口服醋氯芬酸缓释片,连续9天达稳态血药浓度,经时血药浓度变化过程,符合一级吸收的一房室模型。第9天主要药动学参数为:T1/2Ka(h)=1.33±0.27,T1/2Ke=4.64±中0.29,Tmax(h) =3.40±0.50,Cmax(μg·mL-1)=14.41±1.34,Cmin (μg·mL-1)=0.97±0.19,MRT(h)=7.15±0.31,AUCSS(μg·h-1·mL-1)=100.60±14.81, Cav(μg·mL-1)=4.19±0.62,DF(%)=323.98±31.86。
[贮 藏] 密封,在干燥处保存。
[包 装] 铝塑包装,6片/板,1板/盒;6片/板,2板/盒;12片/板,1板/盒。
[有 效 期] 24个月
[执行标准] YBH00212009
[批准文号]国药准字H20090011
[生产企业]
企业名称:浙江尖峰药业有限公司
地 址:浙江省金华市婺城区白汤下线高畈段58号
电 话:0579-82661998(咨询) 0579-82131973(销售)
传 真:0579-82661998
邮 编:321075
网 址:www.zjjfyy.com.cn
More information
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Jianfeng Pharmaceutical Artificial Niuhuang Project Starts
News from this newspaper Jianfeng Pharmaceutical artificial bezoar technical transformation project recently started construction in Qiubin Factory. Artificial bezoar has the effect of clearing away heat and detoxification, resolving phlegm, and is commonly used in Chinese and Western medicines such as colds, clearing away heat and detoxification. As the vast majority of artificial bezoar-related preparations are national essential drugs, with the further implementation of the medical reform policy, the downstream industry of artificial bezoar will enter a new round of business cycle. Jianfeng Pharmaceutical has many years of experience in artificial bezoar production. The technological transformation project will use the existing workshop structure, public works and operators of Qiubin Factory to achieve an annual production capacity of 100 tons of artificial bezoar by adding production equipment such as double cone rotary vacuum drying, horizontal ball mill pulverizer unit, hopper and hoist, closed screening system, and upgrading some public systems. According to the project implementation plan, the project will complete the civil engineering in May. Complete the commissioning, testing and verification of equipment and facilities in July, with trial production conditions; Strive to complete the on-site inspection of GMP certification before the end of December. At present, the factory buildings in Qiubin are vacated and the site is cleaned up. It is understood that the production of natural bezoar is very small, the price is extremely high, and the market rarely provides it. As a biochemical API, artificial bezoar has fewer manufacturers. In the past, due to relatively loose supervision, the testing methods of raw materials and finished products are relatively simple, the quality control indicators are not perfect, and the quality of products on the market is uneven. It is imperative to improve the quality standards. To this end, the State Food and Drug Administration issued the "Biochemical Drug GMP Quality Management Practice (Draft for Comment)" at the end of 2016, which was implemented in March 2017. spike medicine
2020
07-31
Recently, Jianfeng Health has been awarded a number of plaques and certificates by the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City. They are "Zhejiang Science and Technology small and medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprises", "Jinhua Agricultural Science and Technology Research and Development Center" and so on. According to the relevant requirements, Zhejiang science and technology-based small and medium-sized enterprises must be small and medium-sized enterprises with independent intellectual property rights, proprietary technology or advanced knowledge, engaged in the research, development, production, sales and service of high-tech and its products, and the proportion of enterprises engaged in scientific and technological research and development personnel accounting for no less than 10% of the total number of employees in that year. Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016, a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patent and 5 appearance patents had been obtained. High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State, ''and continue to carry out research and development and technological achievements transformation. Their main products (services) have independent intellectual property rights (authorized, registered or accepted). There are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the deep processing technology and equipment of agricultural products, Chinese herbal pieces and plant extracts.
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-30
Peak Pharmaceutical was rated as a national intellectual property advantage enterprises
The score ranked first among Jinhua participating enterprises. A few days ago, Peak Pharmaceutical Company was rated as a national intellectual property advantage enterprise. The selection of national intellectual property advantage enterprises is organized by the State Intellectual Property Office. The purpose is to accelerate the formation of a group of Chinese intellectual property leading enterprises with independent intellectual property rights, well-known brands and international competitive advantages, and achieve the development goal of strong intellectual property enterprises. Since Jianfeng Pharmaceutical introduced the GB-T29490-2013 "Enterprise Intellectual Property Management Standard" in 2013, it has been rated as a patent demonstration enterprise in Zhejiang Province in 2013. In 2014, the "Jianfeng" trademark obtained a famous trademark in Zhejiang Province, and the first edition of the "Intellectual Property Manual" was compiled and implemented in 2015. In 2016, it passed the third-party certification of the GB-T29490-2013 "Enterprise Intellectual Property Management Standard". The "Jianfeng" trademark was rated as a well-known trademark by the State Administration of China. In the application and selection of national knowledge by superior enterprises, 52 enterprises in Zhejiang Province won this honor, ranking second in the country in number; Jianfeng Pharmaceutical ranked first among Jinhua participating enterprises. (Zhang Mingyin)
2020
07-31
Group Party Committee to determine the annual work plan
The party Committee of the group company has determined its work ideas and work plan for 2017 a few days ago, and relevant work has been arranged below. In view of the current new political and economic situation and the task of enterprise transformation and development, the general requirements of the Party Committee of the Group Company for 2017 are: to thoroughly study and implement the spirit of the Sixth Plenary Session of the 18th CPC Central Committee and the series of important speeches by General Secretary Xi Jinping, the spirit of the Seventh Party Congress of Jinhua City, to closely revolve around the center of enterprise production, operation and reform and development, and to adhere to scientific development and cross-regional development as the first priority, in order to continue to carry out the study and education of "five stars striving for innovation" and "two learning and one doing", we should highlight the main line of comprehensively and strictly administering the party according to the rules, firmly establish the political consciousness, overall situation consciousness, core consciousness and alignment consciousness of the majority of Party members and cadres, strengthen and improve the party building work in enterprises in the spirit of reform, and strive to improve the scientific, standardized and institutionalized level of Party building work in enterprises, in order to promote the scientific development of the group company, leapfrog development and harmonious development, it provides a strong political, ideological and organizational guarantee. The working idea of the Party Committee of the Group Company in 2017 is to focus on "one center", adhere to "one concept", highlight "three key points" and do a good job in "three constructions". That is: centering on the "one center" of enterprise production, operation and reform and development, we should strive to strengthen the "one concept" of "the organic unity of the party's leadership and the improvement of corporate governance"; to "thoroughly implement the main responsibility of the party committee; continue to carry out the study and education of" two learning and one doing "; and improve the system of party building work" as the "three key points", and focus on "team building and team building
2020
07-31